

February 21, 2017



## OPKO Health to Participate at Upcoming Healthcare Investment Conferences

MIAMI, Feb. 21, 2017 (GLOBE NEWSWIRE) -- **OPKO Health, Inc.** (NASDAQ:OPK) today announced that senior management will participate at the 2017 RBC Capital Markets' Healthcare Conference taking place February 22-23, 2017 at the New York Palace Hotel and at the Cowen Group's 37<sup>th</sup> Annual Health Care Conference taking place March 6-8, 2017 at The Boston Marriott Copley Place.

### **2017 RBC Capital Markets' Healthcare Conference**

**Date and Time:** Thursday, February 23, 2017, 11:00 AM ET

**Format:** Company presentation

**Presenter:** OPKO Health Senior Management

### **Cowen Group's 37<sup>th</sup> Annual Health Care Conference**

**Date:** March 6, 2017

**Format:** One-on-One Meetings

**Presenter:** OPKO Health Senior Management

The 2017 RBC Capital Markets' Healthcare Conference presentation will be webcast live on the OPKO Investor Relations page of the corporate website at [www.opko.com](http://www.opko.com). To access the live webcast please log onto the OPKO website approximately fifteen minutes before the presentation to register and download any necessary audio software. The audio presentation will be available at this link for a limited time after the live presentation.

### **About OPKO Health, Inc.**

OPKO Health is a diversified healthcare company that seeks to establish industry-leading positions in large, rapidly growing markets. Our diagnostics business includes Bio-Reference Laboratories, the nation's third-largest clinical laboratory with a core genetic testing business and a 400-person sales and marketing team to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros® 1 in-office immunoassay platform. Our pharmaceutical business features RAYALDEE, an FDA-approved treatment for SHPT in stage 3-4 CKD patients with vitamin D insufficiency (launched in November 2016), VARUBI™ for chemotherapy-induced nausea and vomiting (oral formulation launched by partner TESARO and IV formulation pending FDA approval), TT401, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity which is a clinically advanced drug candidate among the new class of GLP-1 glucagon receptor dual agonists, and TT701, an androgen receptor modulator for androgen deficiency indications. Our biologics business includes hGH-CTP, a once-weekly human growth hormone injection (in phase 3 and partnered with Pfizer), a long-acting Factor VIIa drug for hemophilia (in phase 2a) and a long-acting oxyntomodulin for diabetes and obesity (in phase 1). We also have production and distribution assets worldwide, multiple strategic investments and an active business

development strategy. More information is available at [www.opko.com](http://www.opko.com).

Contacts:

OPKO Health, Inc.  
David Malina, 305-575-4100  
Investor Relations

or

Media  
Rooney & Associates  
Terry Rooney, 212-223-0689  
trooney@rooneyco.com

or

Marion Janic, 212-223-4017  
mjanic@rooneyco.com

or

Investors  
LHA  
Anne Marie Fields, 212-838-3777  
afields@lhai.com

or

Bruce Voss, 310-691-7100  
bvoss@lhai.com



Source: OPKO Health Inc.